RET and MEN2 This presentation brought to you by Meredith Stewart.

Slides:



Advertisements
Similar presentations
Clinical Impression: BRONCHOGENIC CARCINOMA. Small cell lung carcinoma 20 % of lung cancer Anaplastic and highly malignant Displays neuroendocrine properties.
Advertisements

Cancer Biology. 2 Outline 1.How do cancer cells differ from normal cells? Tumor progression Molecular basis for cancer.
C-Kit and Gastrointestinal Stromal Tumors By Jessica Danielle Stewart
ZAFIA ANKLESARIA Role of BMPR1A in Juvenile Polyposis Syndrome Biology 169.
RET Multiple Endocrine Neoplasia Type 2 (MEN2) Brooke Martin 3/20/08.
34 Cancer.
Transforming Growth Factor β Receptor Type II Tina Morris
Von Hippel-Lindau Syndrome (VHL) Presented by Kelley Montoya March 20, 2003.
Lecture 23 Signal Transduction 2
Phosphatase and Tensin Homolog Deleted on Chromosome 10
BioSci 145A lecture 18 page 1 © copyright Bruce Blumberg All rights reserved BioSci 145A Lecture 18 - Oncogenes and Cancer Topics we will cover today.
PDGF β Receptor. Protein 1106 amino acid protein Weinberg Fig 5.10.
Tumor Markers Epidemiology 243: Molecular Epidemiology.
Emad Raddaoui, MD, FCAP, FASC Associate Professor; Consultant Histopathology & Cytopathology.
THYROID NODULES AND NEOPLASMS Emad Raddaoui, MD, FCAP, FASC Associate Professor; Consultant Histopathology & Cytopathology.
Colony-Stimulating Factor Receptor (CSF-1R); c-fms.
Chapter 20 oncogene, anti-oncogene and growth factor The biochemistry and molecular biology department of CMU.
RET Proto-Oncogene of Multiple Endocrine Neoplasia type 2(MEN2)
RET Proto- Oncogene in The Development of Thyroid Cancer: Multiple Endocrine Neoplasia Type 2 Courtney Brooks.
Tumor Supressor Gene Non-functional TSG Mutations increasing risk of cancer “Loss of function” mutation Proto-oncogene Oncogene (Hyperactive or unregulated.
Thyroid nodules and neoplasms EMAD RADDAOUI, MD, FCAP, FASC ASSOCIATE PROFESSOR; CONSULTANT HISTOPATHOLOGY & CYTOPATHOLOGY.
By the end of this lecture, students will learn: 1.Oncogenes 2.Tumor suppressor genes. 3.DNA Repair genes 4.Genes Associated with Cancer Intended Learning.
NOTES: CH 18 part 2 - The Molecular Biology of Cancer
Cancer &Oncogenes. Objectives Define the terms oncogene, proto-oncogenes and growth factors giving examples. Describe the mechanisms of activations of.
LE 12-2b Growth and development 200 µm. LE 12-2c Tissue renewal 20 µm.
Monomeric G proteins Alice Skoumalová. 1.General features of chemical messengers - types of receptors 2.Endocrine, paracrine and autocrine actions 3.Examples.
23.1 Cancer Is a Group of Diseases Characterized by Cell Proliferation.
Cancer occurs when there is a loss in the control of the cell cycle. There are many controls of the cell cycle. There are many types of cancer.
Gihan E-H Gawish, MSc, PhD Ass. Professor Molecular Genetics and Clinical Biochemistry Molecular Genetics and Clinical BiochemistryKSU 8 TH WEEK.
Genetics of Cancer Genetic Mutations that Lead to Uncontrolled Cell Growth.
Essentials of Biology Sylvia S. Mader
Ishita Das
oncogene, anti-oncogene and growth factor
Benign Versus Malignant Tumors
Javad Jamshidi Fasa University of Medical Sciences, November 2015 Session 9 Medical Genetics Cancer Genetics.
CHAPTER 19 THE ORGANIZATION AND CONTROL OF EUKARYOTIC GENOMES Copyright © 2002 Pearson Education, Inc., publishing as Benjamin Cummings Section D: The.
BIOLOGY CONCEPTS & CONNECTIONS Fourth Edition Copyright © 2003 Pearson Education, Inc. publishing as Benjamin Cummings Neil A. Campbell Jane B. Reece Lawrence.
Lecture 12: Cancer: a cellular perspective Dr. Mamoun Ahram Faculty of Medicine Second year, Second semester, Principles of Genetics and Molecular.
Oncogenes Lecture 43BSCI 420,421,620Dec 13, 2002 “It ain’t over till the fat lady sings” – Joe Gibbs 1.Cancer-critical genes a. Oncogenes b. Tumor-suppressor.
Types of Genes Associated with Cancer
TSC1/Hamartin and Facial Angiofibromas Biology 169 Ann Hau.
PTEN (Cowden Syndrome) /.../ sld083.htm.
PTEN (Phosphatase and Tensin Homolog) a.k.a. MMAC1, TEP1 Raymond Stadiem.
Thyroid nodules and neoplasms. Upon completion of this lecture the students will be able to: Understand the concept of diffuse and multinodular goiter.
Adrenal Physiology David Feldman Glucocorticoids Mineralocorticoids Catecholamines/Adrenal Medulla Adrenal Causes of Hypertension ◦ Cushings Syndrome ◦
Chapter 11 Cancer Genetics. Cell responses to environmental signals.
Biology of Cancer Weeks 1 Introduction and 2 RTKs Dr. Michael Chorney Susquehanna Medicine and Health Science Magnet February 17 th -28 th, 2014.
M ULTIPLE E NDOCRINE N EOPLASIA T YPE II: S URGICAL M ANAGEMENT Greta Riedesel, R3 12/9/2010.
Cancer. Cancer is a disease of the cell cycle Caused by one or more of the following: Increase in growth signals Loss of inhibitory signals In addition,
Virginia Sanders, MD PGY-1
Cancer The biological formation of cancer and treatments for the disease.
Integrin-EGFR Cross-Activation Elizabeth Brooks Department of Chemical Engineering University of Massachusetts, Amherst Peyton Lab Group Meeting December.
Medullary Carcinoma of the Thyroid Karl Rice. Causes Diagnosis and Treatment Medullary thyroid carcinoma originates from the parafollicular cells (C cells)
Date of download: 9/17/2016 Copyright © 2016 McGraw-Hill Education. All rights reserved. Schematic comparison of structural features of cell surface growth.
THE GENETIC BASIS OF CANCER
Schematic comparison of structural features of cell surface growth factor receptor tyrosine kinases and membrane-associated tyrosine kinase oncogene products.
Familial Thyroid Carcinoma
Peyton Rous discovered a virus that causes cancer in chickens
and multiple endocrine neoplasia type 2 (MEN2)
Concept 18.5: Cancer results from genetic changes that affect cell cycle control The gene regulation systems that go wrong during cancer are the very same.
Genetics of Cancer.
M.B.Ch.B, MSC, DCH (UK), MRCPCH
PTEN (a.k.a. MMAC1 and TEP1) and Cowden’s Disease
Extracellular Regulation of Apoptosis
Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer  Roberto Ferrara, MD, Nathalie Auger, MD, Edouard Auclin,
PTEN Tumor Suppressor and Cancer
M.B.Ch.B, MSC, PhD, DCH (UK), MRCPCH
RET Receptor Ashley Bass.
Multiple Endocrine Neoplasia Type 2B and Hirschsprung’s Disease
Figure 2 Mechanisms of RET activation in cancer
Presentation transcript:

RET and MEN2 This presentation brought to you by Meredith Stewart

The Disease: MEN = Multiple endocrine neoplasia

MEN 2 Cancers Familial Medullary Thyroid Carcinoma Familial Medullary Thyroid Carcinoma MEN 2A MEN 2A MEN 2B MEN 2B Medullary thyroid carcinoma (C cells) Medullary thyroid carcinoma (C cells) Pheochromocytoma (adrenal tumors) Pheochromocytoma (adrenal tumors) Parathyroid hyperplasia Parathyroid hyperplasia

Autosomal dominant inheritance Autosomal dominant inheritance Nearly 100 % penetrance Nearly 100 % penetrance 1 case out of 30,000 – 50,000 people 1 case out of 30,000 – 50,000 people Treatment options: Treatment options: –Remove the thyroid –Inhibit malfunctioning protein’s action MEN 2 Cancer, con’t:

RET = The Bad Guy (Rearranged during Transfection) Proto-oncogene Proto-oncogene Receptor tyrosine kinase Receptor tyrosine kinase

RET = The Bad Guy (Rearranged during Transfection) Proto-oncogene Proto-oncogene Receptor tyrosine kinase Receptor tyrosine kinase One of pathways is in fact Ras  MAPK One of pathways is in fact Ras  MAPK

Many paths to follow…

A less detailed view Coreceptor = GFRα family Coreceptor = GFRα family Ligand = GFL family Ligand = GFL family Cysteine region autophosphorylates when bound by ligand Cysteine region autophosphorylates when bound by ligand Phosphorylates other substrates Phosphorylates other substrates

“The activation of the RET pathway results in increased cell motility, dissociation of cell adhesion, and the migration towards a localized source of GDNF. Cellular responses to RET include the formation of lamellipodia, filopodia, and reorganization of the actin cytoskeleton.” -Tang, Worley, Sanicola and Dressler, 1998 Normal RET Function?

Homozygous knockouts have no kidneys!!! Knockout Mice

Normal RET Function? Homozygous knockouts have no kidneys!!! Knockout Mice

“The activation of the RET pathway results in increased cell motility, dissociation of cell adhesion, and the migration towards a localized source of GDNF. ” -Tang, Worley, Sanicola and Dressler, 1998 …such as a ureteric bud growing towards some mesenchymal cells to form kidneys… Normal RET Function?

RET expressed at different points of development of organism (and differently in organism) RET expressed at different points of development of organism (and differently in organism)

What goes wrong in cancer? Proto-oncogene  constituvely active Proto-oncogene  constituvely active

What goes wrong in cancer? Proto-oncogene  constituvely active Proto-oncogene  constituvely active FMTC: cysteine mutation (extracellular domain) FMTC: cysteine mutation (extracellular domain) MEN 2A: cysteine mutation at codon 634 MEN 2A: cysteine mutation at codon 634

What goes wrong in cancer? Proto-oncogene  constituvely active Proto-oncogene  constituvely active FMTC: cysteine mutation (extracellular domain) FMTC: cysteine mutation (extracellular domain) MEN 2A: cysteine mutation at codon 634 MEN 2A: cysteine mutation at codon 634 MEN 2B: kinase mutation at codon 918 MEN 2B: kinase mutation at codon 918

When RET goes bad… Loss of function RET leads to Hirschsprung disease (recessive) Loss of function RET leads to Hirschsprung disease (recessive) Overactive RET can also lead to papillary thryoid cancer Overactive RET can also lead to papillary thryoid cancer

BUT LOOK!!! Washington University School of Medicine performed this experiment: The third eye shown was treated during development with kinase inhibitor zd6474 and mostly rescued Normal RETToo much RETToo much RET + zd6474

Works Referenced L. Alberti, C. Carniti, C. Miranda, E. Roccatto, and M. Pierotti. “RET and NRTK1 Proto- Oncogenes in Human Diseases.” Journal of Cellular Physiology 195 (2003): 168—186. L. Alberti, C. Carniti, C. Miranda, E. Roccatto, and M. Pierotti. “RET and NRTK1 Proto- Oncogenes in Human Diseases.” Journal of Cellular Physiology 195 (2003): 168—186. J. Hansford and L. Mulligan. “Multiple endocrine neoplasia type 2 and RET: from neoplasia and neurogenesis.” Journal of Medical Genetics 37 (2003): 817—827. J. Hansford and L. Mulligan. “Multiple endocrine neoplasia type 2 and RET: from neoplasia and neurogenesis.” Journal of Medical Genetics 37 (2003): 817—827. Hofstra, Robert M.W. “The RET gene and its associated diseases.” Diss. Department of Medical Genetics, University of Groningen. Netherlands: —19. Accessed at Hofstra, Robert M.W. “The RET gene and its associated diseases.” Diss. Department of Medical Genetics, University of Groningen. Netherlands: —19. Accessed at M. Ichihara, Y. Murakumo, and M. Takahashi. “RET and neuroendocrine tumors.” Cancer Letters 204 (2004): 197—211. M. Ichihara, Y. Murakumo, and M. Takahashi. “RET and neuroendocrine tumors.” Cancer Letters 204 (2004): 197—211. S. Manie, M. Santoro, A. Fusco and M. Billaud. “The RET receptor: function in development and dysfunction in congenital malformation.” TRENDS in Genetics 17 (2001): 580—589. S. Manie, M. Santoro, A. Fusco and M. Billaud. “The RET receptor: function in development and dysfunction in congenital malformation.” TRENDS in Genetics 17 (2001): 580—589. M. Tang, D. Worley, M. Sanicola, and G. Dressler. “The RET-Glial Cell-derived Neurotrophic Factor (GDNF) Pathway Stimulates Migration and Chemoattraction of Epithelial Cells.” The Journal of Cell Biology 142 (1998): 1337—1345. M. Tang, D. Worley, M. Sanicola, and G. Dressler. “The RET-Glial Cell-derived Neurotrophic Factor (GDNF) Pathway Stimulates Migration and Chemoattraction of Epithelial Cells.” The Journal of Cell Biology 142 (1998): 1337—1345. M. Vidal, S. Wells, R. Anderson, and R. Cagan. “ZD6474 Suppresses Oncogenic RET Isoforms in a Drosophila Model for Type 2 Multiple Endocrine Neoplasia Syndromes and Papillary Thyroid Carcinoma.” Cancer Research 65 (2005): 3538—3541. M. Vidal, S. Wells, R. Anderson, and R. Cagan. “ZD6474 Suppresses Oncogenic RET Isoforms in a Drosophila Model for Type 2 Multiple Endocrine Neoplasia Syndromes and Papillary Thyroid Carcinoma.” Cancer Research 65 (2005): 3538—3541. (Basic information about different types of cancer was searched for at (Basic information about different types of cancer was searched for at